"The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023"
This article gives a comprehensive overview of the use of GLP1R agonists for the treatment of T2D
A cohort study revealed an increased risk of pancreatitis, and 36% of patients who used GLP-1 RAs or DPP- 4 inhibitors had elevated serum amylase or lipase (or both) levels compared with 18% of patients not taking these agents ( Our studies showed GLP-1 RA-associated gastrointestinal toxicities occurred 30 days (3,234, 77.44%) after the initiation of GLP-1RAs, and the median time-to-onset was 1 (IQR 024) days with a significant difference between different GLP-1 RA regimens
While hypoperfusion likely plays a role, oxidative stress and subsequent renal tissue damage from reactive oxygen species occurs due to both ischemia-reperfusion injury and activation of inflammatory cascades when blood is exposed to the CPB circuit [37]
BPC 157 maintains the normal functions of cells by enhancing their antioxidant capacity and protecting them from the attack of free radicals
CACT is a reverse transport protein that uses electrochemical gradients to exchange acylcarnitine in the cytoplasm with free carnitine in the matrix, achieving net transport of acyl groups